Abstract
The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use*
-
Axitinib
-
Benzenesulfonates / therapeutic use
-
Bevacizumab
-
Carcinoma, Renal Cell / drug therapy*
-
Clinical Trials as Topic
-
Everolimus
-
Humans
-
Imidazoles / therapeutic use
-
Indazoles / therapeutic use
-
Indoles / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Neoplasm Metastasis
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Pyridines / therapeutic use
-
Pyrimidines / therapeutic use
-
Pyrroles / therapeutic use
-
Sirolimus / analogs & derivatives
-
Sirolimus / therapeutic use
-
Sorafenib
-
Sulfonamides / therapeutic use
-
Sunitinib
-
Vascular Endothelial Growth Factors / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Benzenesulfonates
-
Imidazoles
-
Indazoles
-
Indoles
-
Phenylurea Compounds
-
Pyridines
-
Pyrimidines
-
Pyrroles
-
Sulfonamides
-
Vascular Endothelial Growth Factors
-
Niacinamide
-
Bevacizumab
-
temsirolimus
-
pazopanib
-
Everolimus
-
Sorafenib
-
Axitinib
-
Sunitinib
-
Sirolimus